期刊论文

Shi, Ming

英文

JAMA ONCOLOGY

2374-2437

2019

5

7

953-960

10.1001/jamaoncol.2019.0250

accuracy of the data analysis. Drs He, Li, Zou, and Shen contributed equally to the work. Study concept and design: He, Xu, Shi. Acquisition, analysis, or interpretation of data: He, Li, Zou, Shen, Fang, Tan, Y. Zhou, Wu, Wei, Le, Z. Zhou, Zhao, Y. Guo, R. Guo, Chen, Shi. Drafting of the manuscript: He, Li, Shen, Xu, Shi. Critical revision of the manuscript for important intellectualcontent:He,Li,Zou,Fang,Tan,Y.Zhou,Wu, Wei, Le, Z. Zhou, Zhao, Y. Guo, R. Guo, Chen, Shi. Statistical analysis: He, Li, Y. Guo, Shi. Obtained funding: Shi. Administrative, technical, or material support: He, Zou, Shen, Fang, Tan, Y. Zhou, Wu, Xu, Wei, Le, Z. Zhou, Zhao, R. Guo, Chen, Shi. Study supervision: He, Shi. Conflict of Interest Disclosures: None reported. Funding/Support: This work was supported by National Key R&D Program of China (2017YFA0505803), the National Natural Science Foundation of China (No. 81625017,No.81572385), National Science and Technology Major Project of China (2018ZX10302205), and the Fundamental Research Funds for the Central Universities of China (No. 16ykjc36).

本校为其他机构

Importance  Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promising results for these patients in a previous phase 2 study. Objective  To investigate the efficacy and safety of sorafenib plus HAIC compared with sorafenib for hepatocellular carcinoma with portal vein invasion. Design, Setting, and Participants &...